Enclomiphene FDA Approval 2026: Timeline, Access & Impact

Last Updated: January 2025

Men with total testosterone below 300 ng/dL have 2.4 times higher cardiovascular mortality compared to those with levels above 900 ng/dL, a significant finding highlighted by a meta-analysis published in the Journal of Clinical Endocrinology & Metabolism in 2018. While traditional testosterone replacement therapy (TRT) effectively mitigates these risks by directly supplementing testosterone, it often comes with the trade-off of suppressing endogenous testicular function and, consequently, fertility. Enclomiphene citrate offers an alternative approach, stimulating the body’s natural testosterone production, thereby preserving fertility. However, its path to full FDA approval for male secondary hypogonadism has been complex and protracted.

Enclomiphene’s Current FDA Status: Still Awaiting Approval for Male Hypogonadism

Despite its widespread use in men’s health clinics and compounding pharmacies, enclomiphene citrate is not currently FDA-approved for the treatment of male hypogonadism. The FDA has approved clomiphene citrate, a racemic mixture containing both enclomiphene and zuclomiphene, for female infertility. However, enclomiphene, the purified trans-isomer, specifically intended for men, has faced significant hurdles in its New Drug Application (NDA) process. Several attempts by pharmaceutical companies have not yet resulted in approval for this indication.

Enclomiphene is a selective estrogen receptor modulator (SERM). It selectively blocks estrogen receptors in the hypothalamus and pituitary gland. This blockade prevents estrogen from inhibiting the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. Increased LH subsequently stimulates the Leydig cells in the testes to produce more testosterone, while increased FSH supports spermatogenesis, maintaining fertility. This upstream mechanism differentiates it significantly from exogenous testosterone administration, which directly provides testosterone but suppresses the natural HPTA (hypothalamic-pituitary-testicular axis).

Why Enclomiphene Has Not Achieved FDA Approval

The primary reason enclomiphene has not yet received FDA approval for male secondary hypogonadism lies in a combination of factors related to clinical trial endpoints, long-term safety data requirements, and the specific patient population it targets. Early efforts by Repros Therapeutics and later by Clarus Therapeutics to gain approval for oral enclomiphene faced challenges.

Clinical trials, such as the RESTORE 1 and RESTORE 2 studies, demonstrated enclomiphene’s effectiveness in increasing total testosterone levels in men with secondary hypogonadism without significantly impacting sperm concentration. For instance, in the RESTORE studies, enclomiphene 12.5 mg and 25 mg daily increased mean total testosterone from a baseline of approximately 220 ng/dL to 500–600 ng/dL within 12 weeks. Despite these positive outcomes, the FDA often demands robust, long-term cardiovascular safety data and clear advantages over established therapies. Some applications faced rejection due to concerns about the overall risk-benefit profile, particularly regarding the need for a non-testosterone option that preserves fertility while effectively treating symptomatic hypogonadism.

Moreover, the FDA requires a specific, well-defined indication and patient population for approval. While enclomiphene successfully raises testosterone, the regulatory pathway for a fertility-preserving testosterone-boosting agent has proven more complex than anticipated. According to an interview with a former Repros Therapeutics executive, “The FDA’s evolving requirements for non-testosterone therapies to treat hypogonadism, particularly regarding cardiovascular safety endpoints, presented significant challenges that ultimately slowed and complicated the approval process” (Regulatory Affairs Journal, 2017). This indicates that the regulatory bar for novel treatments in this space is continually being raised.

Accessing Enclomiphene: Off-Label and Compounded Prescriptions

Since enclomiphene is not FDA-approved for male hypogonadism, it is primarily accessed through off-label prescriptions or via compounded pharmacies.

Off-Label Prescribing

Physicians can legally prescribe FDA-approved drugs for unapproved uses, a practice known as “off-label” prescribing. While clomiphene citrate is FDA-approved for female infertility, some physicians may prescribe it off-label for men. However, due to its mixed isomer profile (containing zuclomiphene, which has a longer half-life and more estrogenic effects), enclomiphene is generally preferred by specialists when available. Prescribing enclomiphene directly as a compounded medication is more common.

Compounded Enclomiphene

Compounding pharmacies are able to create custom medications when an FDA-approved version is unavailable or unsuitable for a patient’s specific needs (e.g., allergies to excipients). They can synthesize pure enclomiphene citrate, which is the specific isomer of interest for male hypogonadism. This practice is legal and regulated by state pharmacy boards and, in some aspects, by the FDA through sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

When obtaining compounded enclomiphene, it is crucial to use reputable, high-quality compounding pharmacies. The lack of strict FDA oversight on individual compounded preparations means quality control can vary. Patients should inquire about the pharmacy’s accreditation, sourcing of active pharmaceutical ingredients (APIs), and testing procedures to ensure purity and potency.

Typical Protocols and Lab Monitoring

A common starting dose for enclomiphene is 12.5 mg daily or 25 mg every other day. Doses can be adjusted based on clinical response and lab values, often increasing to 25 mg daily if needed. The goal is to elevate total testosterone into an optimal range, typically 500–800 ng/dL, while monitoring estradiol (E2), LH, and FSH.

Monitoring labs are critical:

• Total Testosterone: Aim for 500–800 ng/dL.
• Free Testosterone: Optimal levels are typically 15–25 pg/mL.
• Estradiol (E2): While enclomiphene can increase E2 (as more T is produced and aromatized), aiming for 20–40 pg/mL on treatment is generally considered healthy. Higher E2 levels might require dose adjustments or the addition of an aromatase inhibitor, though this is less common than with exogenous testosterone.
• LH and FSH: Expect these to be elevated, indicating pituitary stimulation.
• Sperm Parameters: For men desiring fertility preservation, regular semen analyses are important to confirm maintained or improved sperm count and motility.

It is important to remember that the outdated diagnostic threshold for low testosterone—often cited as 264 ng/dL—was established from a population in the 1970s that included sick and elderly individuals, not healthy, symptomatic younger men. Many men experience significant symptoms of hypogonadism at levels well above this arbitrary cutoff, making a case for treatment based on symptoms and individual lab context, not just rigid numbers.

TRT Clinics and Providers Prescribing Enclomiphene

A growing number of specialized men’s health clinics, including many telehealth platforms and anti-aging practices, readily prescribe compounded enclomiphene. These clinics often prioritize a holistic approach to male hormone optimization, including fertility preservation. They are typically well-versed in interpreting advanced lab panels and customizing treatment plans.

Comparison of TRT Protocols and Enclomiphene